Would you offer immunotherapy in addition to chemotherapy and trastuzumab for patients with metastatic HER2 positive gastroesophageal cancer with low PDL1?
KEYNOTE 811 showed improved response rate with the addition of pembrolizumab, but very few patients in this study had low PDL1.
Answer from: Medical Oncologist at Academic Institution
This is a good question, for which I don't think we'll ever have a satisfactory answer. Indeed, in KEYNOTE 811, about 85% of patients had tumors with a PD-L1 CPS of >1. In the subgroup analysis in the published manuscript (Janjigian et al., PMID 34912120), only 35 of the 264 patients include...
Sign in or Register to read more